Anabel is a Reporter, working across the six Citeline publications. She is a recent graduate from the University of Exeter and holds a BA English degree. Since graduating, Anabel has also completed an editorial internship with the In Vivo team. Before joining Norstella she spent the past year as Editor-in-Chief of her university’s student paper, Exeposé, managing an editorial team to produce a 32-page paper on a fortnightly basis.
Latest from Anabel Costa-Ferreira
The European Medicines Agency is conducting a public consultation on proposed revisions to its policy on how it handles any conflicts of interest of its scientific committee members and experts.
The deadline for comments is nearing for a draft UK guidance that seeks to increase inclusivity and diversity across clinical trials and investigations.
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.
Charles Cooper, CMO of the diagnostics firm bioMérieux, talks to In Vivo about the vital nature of partnerships to fight the global AMR crisis.
BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.
Richard Lowenthal, co-founder and CEO of ARS Pharmaceuticals, highlights the crucial unmet need for needle-free devices to treat type 1 allergic reactions, given challenges associated with current epinephrine injectors. Hear what’s next for the Neffy intranasal spray and ARS Pharmaceuticals.